Head-to-head · WeighScore
REMEVi vs Remote Pharmacy
By GLP-1 ScorecardUpdated
Score comparison
REMEVi has the higher recorded score — 73.5/100 to 69.9/100.
REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
Before you choose
Before comparing the headline prices, the REMEVi review and the Remote Pharmacy review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, REMEVi vs Somi Health and Remote Pharmacy vs Somi Health compare each of them with another graded program, and the list of alternatives to REMEVi ranks the programs closest to REMEVi on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the GoodLife Health review covers one graded close to these two, at 69.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | REMEVi | Remote Pharmacy |
|---|---|---|
| WeighScore | 73.5/100 | 69.9/100 |
| Grade | C | C |
| Site position | #76 | #124 |
| Semaglutide | $143/mo month-to-month ($96/mo on 12-month plan, $1,248 upfront; compounded) | $139/mo month-to-month ($100/mo on 12-month supply, $1,199 upfront; compounded) |
| Tirzepatide | $224/mo month-to-month ($168/mo on 12-month plan, $2,184 upfront; compounded) | $159/mo month-to-month ($125/mo on 12-month supply, $1,499 upfront; compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Strengths
- A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
- Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
- A daily oral semaglutide tablet is offered alongside the injection
- Available in all 50 states and DC, with no minimum commitment and no cancellation fee
What to consider
- The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
- No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Strengths
- Low cash-pay pricing with no subscription or hidden fees
- Free doctor consultation and free shipping (you pay only for medication)
- Offers injectable and sublingual or tablet forms of both drugs
- Medication made by 503A-certified compounding facilities
What to consider
- Does not publicly name its specific compounding pharmacies or clinical provider
- Covered states are not listed on the pages reviewed
- Newer brand with limited third-party track record
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.